Last updated on September 2016

A 12-week, double blind, randomised, placebo controlled, parallel group trial followed by a single active arm phase of 40 weeks evaluating the effect of oral nintedanib 150 mg twice daily on change in biomarkers of extracellular matrix (ECM) turnover in patients with idiopathic pulmonary fibrosis (IPF) and limited forced vital capacity (FVC) impairment.


Brief description of study

A 12-week, double blind, randomised, placebo controlled, parallel group trial followed by a single active arm phase of 40 weeks evaluating the effect of oral nintedanib 150 mg twice daily on change in biomarkers of extracellular matrix (ECM) turnover in patients with idiopathic pulmonary fibrosis (IPF) and limited forced vital capacity (FVC) impairment.

Detailed Study Description

This study is being done to learn more about the study drug, Nintedanib, and to learn if there are blood tests that can help see how the study drug affects IPF.

Clinical Study Identifier: TX11558

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Kathleen McNulty, MHS, CCRC

The Lung Research Center
Chesterfield, MO USA
  Connect »